litlas
Log inCreate account

Howard A. Burris

Active 1992–2025

224
Papers
61,530
Citations
115
h-index
221
i10-index

Citations

Citations per year for Howard A. Burris1964: 1 citations1976: 1 citations1993: 2 citations1994: 12 citations1995: 16 citations1996: 23 citations1997: 30 citations1998: 32 citations1999: 67 citations2000: 64 citations2001: 70 citations2002: 87 citations2003: 107 citations2004: 98 citations2005: 158 citations2006: 155 citations2007: 164 citations2008: 246 citations2009: 284 citations2010: 313 citations2011: 338 citations2012: 396 citations2013: 584 citations2014: 632 citations2015: 669 citations2016: 710 citations2017: 851 citations2018: 855 citations2019: 2,264 citations2020: 2,310 citations2021: 2,176 citations2022: 1,839 citations2023: 1,572 citations2024: 2,362 citations2025: 1,246 citations2026: 34 citations1965–1975: no citations, so these years are not shown1977–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 8,012 citing papers, 27.6% of this breakdownChina: 2,967 citing papers, 10.2% of this breakdownItaly: 1,749 citing papers, 6% of this breakdownUnited Kingdom: 1,652 citing papers, 5.7% of this breakdownGermany: 1,464 citing papers, 5% of this breakdownFrance: 1,384 citing papers, 4.8% of this breakdownSpain: 1,113 citing papers, 3.8% of this breakdownJapan: 925 citing papers, 3.2% of this breakdownCanada: 916 citing papers, 3.2% of this breakdownNetherlands: 812 citing papers, 2.8% of this breakdownAustralia: 760 citing papers, 2.6% of this breakdownSwitzerland: 737 citing papers, 2.5% of this breakdown
0%27.6%Other 22.6%

Institutions

Fields

  • Medicine64.2%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology4%
  • Materials Science1.1%
  • Engineering0.7%
  • Neuroscience0.6%
  • Other2.5%

Topics

  • Cancer Immunotherapy and Biomarkers5.4%
  • HER2/EGFR in Cancer Research3.8%
  • Advanced Breast Cancer Therapies3%
  • Pancreatic and Hepatic Oncology Research2.9%
  • Colorectal Cancer Treatments and Studies2.5%
  • Cancer Genomics and Diagnostics2.4%
  • Other80%

Coauthors

All papers

Open in search
  1. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

    Authors: Do‐Youn Oh, Aiwu Ruth He, Shukui Qin, Li‐Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Mairéad G. McNamara, Renata Zaucha, Antonio Avallone, Benjamin Tan, Juan Cundom, Choong‐kun Lee, Hidenori Takahashi, Masafumi Ikeda, Jen‐Shi Chen, Julie Wang, Mallory Makowsky, Nana Rokutanda, Philip He, John F. Kurland, Gordon Cohen, Juan W. Valle - NEJM Evidence 2022 cited by 1,092

  2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    Authors: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 cited by 3,714

  3. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Authors: Paul M. Ridker, Jean MacFadyen, Tom Thurén, Brendan M Everett, Peter Libby, Robert J. Glynn, Paul M. Ridker, Alberto Lorenzatti, Henry Krum, George Varigos, Peter Siostrzonek, Peter Sinnaeve, Francisco Antônio Helfenstein Fonseca, José Carlos Nicolau, Nina Gotcheva, Jacques Genest, Yong Huo, Miguel Urina‐Triana, Davor Miličić, Renata Cífková, Riina Vettus, Wolfgang Köenig, S.D. Anker, Athanasios Manolis, Fernando Wyss, Tamás Forster, Axel F. Sigurðsson, Prem Pais, Alessandro Fucili, Hisao Ogawa, Hiroaki Shimokawa, Irina Veze, Birutė Petrauskienė, Leon Salvador, John J.P. Kastelein, Jan H. Cornel, Tor Ole Klemsdal, Félix Medina, Andrzej Budaj, L Vida-Simiti, Zhanna Kobalava, Petar Otašević, Daniel Pella, Mitja Lainščak, Ki‐Bae Seung, Patrick Commerford, Mikael Dellborg, Marc Y. Donath, Juey‐Jen Hwang, Hakan Kültürsay, Marcus Flather, Christie M. Ballantyne, Seth Bilazarian, William H. Chang, Cara East, Brendan Everett, Les B. Forgosh, Robert J. Glynn, Barry Harris, Peter Libby, M Ligueros, Tom Thurén, Erin A. Bohula, Bindu Charmarthi, Susan Cheng, Sherry Chou, Jacqueline Suk Danik, Graham T. McMahon, Bradley A. Maron, MingMing Ning, Benjamin A. Olenchock, Reena L. Pande, Todd S. Perlstein, Aruna D. Pradhan, Natalia S. Rost, Aneesh B. Singhal, Viviany R. Taqueti, Nancy Wei, Howard A. Burris, Angela Cioffi, Anne Marie Dalseg, Nilanjan Ghosh, Julie R. Gralow, Tina Mayer, Hope S. Rugo, Vance G. Fowler, Ajit P. Limaye, Sara E. Cosgrove, Donald P. Levine, Renato D. Lópes, John Scott, Tom Thurén, M Ligueros, Robert Hilkert, Georgia Tamesby, Carolyn Mickel, Brian Manning, Julian Woelcke, Monique Tan, S Manfreda and 19 more - The Lancet 2017 cited by 1,308

  4. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    Authors: Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 713

  5. openalex_id:w4221085715

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Lowell L. Hart, Mario Campone, Katarína Petráková, Eric P. Winer, Wolfgang Janni, PierFranco Conte, David Cameron, Fabrice André, Carlos L. Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy cited by 579

  6. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 cited by 2,009

  7. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    Authors: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 cited by 2,828

  8. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

    Authors: Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, M R Green, Mace L. Rothenberg, Manuel Modiano, M. Christine Cripps, Russell K. Portenoy, Anna Maria Storniolo, Peter G. Tarassoff, Ryan Nelson, F. Andrew Dorr, Connie Stephens, Daniel D. Von Hoff - Journal of Clinical Oncology 1997 cited by 5,884

  9. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

    Authors: John H. Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, Elena Élez, David L. Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios Bekaii‐Saab, Eric Van Cutsem, Marc Peeters, Marc Van den Evnde, Thierry André, Christophe Borg, Matthieu Sarabi, François Ghiringhelli, Benoist Chibaudel, Salvatore Siena, Chiara Cremolini, Maria Giulia Zampino, Elena Élez, Susana R. Keranen, Ramón Salazar, Pilar Alfonso, John H. Strickler, Andrea Cercek, Kimmie Ng, Christina Wu, Andrew Scott Paulson, Joleen M. Hubbard, Andrew L. Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon Murtaza Kasi, Heinz‐Josef Lenz, Kristen K. Ciombor, David L. Bajor, Tanios Bekaii‐Saab, Olumide B. Gbolahan, Patrick M. Boland, Daniel Berg, Federico Sanchez, Timothy F. Goggins, Federico Sanchez, Howard A. Burris, Johanna C. Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel V.T. Catenacci, Jun Gong, Ignacio Garrido‐Laguna, Gene Grant Finley, Benjamin A. Weinberg, Anthony F. Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher S. Chen, James M. Ford, Madappa N. Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer H. Shao, Scott McKenney, Spencer H. Shao - The Lancet Oncology 2023 cited by 245

  10. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

    Authors: Funda Meric‐Bernstam, Herbert I. Hurwitz, Kanwal Raghav, Robert R. McWilliams, Marwan Fakih, Ari M. Vanderwalde, Charles Swanton, Razelle Kurzrock, Howard A. Burris, Christopher J. Sweeney, Ron Bose, David R. Spigel, Mary Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John D. Hainsworth - The Lancet Oncology 2019 cited by 564

  11. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    Authors: Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris - EClinicalMedicine 2021 cited by 275

  12. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

    Authors: Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou‐Alfa, Ben George, John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard A. Burris - The Lancet Oncology 2021 cited by 406

  13. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

    Authors: Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak - Journal of Clinical Oncology 2022 cited by 186

  14. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Authors: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 cited by 2,430

  15. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    Authors: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 cited by 2,798

  16. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

    Authors: Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Melissa L. Johnson, Howard A. Burris, Francisco Robert, Tae Hyung Han, Sheila Bheddah, Noah Theiss, Sky Watson, Deepan Mathur, Bharathi Vennapusa, Hany Zayed, Satwant Lally, Donald K. Strickland, Ramaswamy Govindan, Scott J. Dylla, Stanford L. Peng, David R. Spigel - The Lancet Oncology 2016 cited by 553

  17. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

    Authors: Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth A. Maher, Macarena I. de la Fuente, Matthias Holdhoff, Gregory M. Coté, Howard A. Burris, Filip Jankú, Robert J. Young, Raymond Y. Huang, Liewen Jiang, Sung Choe, Bin Fan, Katharine Yen, Min Lu, Chris Bowden, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen - Journal of Clinical Oncology 2020 cited by 307

  18. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

    Authors: Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú, Gregory M. Coté, Macarena I. de la Fuente, Jennifer Clarke, Benjamin M. Ellingson, Saewon Chun, Robert J. Young, Hua Liu, Sung Choe, Min Lu, Kha Le, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Timothy F. Cloughesy, Patrick Y. Wen - Clinical Cancer Research 2021 cited by 259

  19. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

    Authors: Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiß-Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga - Journal of Clinical Oncology 2018 cited by 439

  20. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

    Authors: Do‐Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li‐Tzong Chen, Masayuki Kitano, Choong‐kun Lee, Jin Won Kim, Ming‐Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen‐Shi Chen, Piotr Potemski, Howard A. Burris, Vikas Ostwal, Suebpong Tanasanvimon, Chigusa Morizane, Renata Zaucha, Mairéad G. McNamara, Antonio Avallone, Juan E Cundom, В. В. Бредер, Benjamin Tan, Satoshi Shimizu, David Tougeron, Ludovic Evesque, Mila Petrova, David B. Zhen, Roopinder Gillmore, Vineet Gupta, Farshid Dayyani, Joon Oh Park, Gary L. Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W. Valle - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 254

  21. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Authors: Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso, Andrés Cervantes, Gary K. Schwartz, Glen J. Weiss, Luis Paz‐Ares, Daniel C. Cho, Jeffrey R. Infante, María Alsina, Mrinal M. Gounder, Rick Falzone, Jamie Harrop, Amy C. Seila White, Iva Toudjarska, David Bumcrot, Rachel Meyers, Gregory Hinkle, Nenad Svrzikapa, Renta Hutabarat, Valerie A. Clausen, Jeffrey Cehelsky, Saraswathy V. Nochur, Christina Gamba‐Vitalo, Akshay Vaishnaw, Dinah W.Y. Sah, Jared Gollob, Howard A. Burris - Cancer Discovery 2013 cited by 699

  22. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Authors: John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock - Journal of Clinical Oncology 2018 cited by 505

  23. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

    Authors: Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, R. Borson, Steven Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard A. Michaelson, Sandhya Girish, Lukas C. Amler, Maoxia Zheng, Yu-Waye Chu, Barbara Klencke, Joyce O’Shaughnessy - Journal of Clinical Oncology 2010 cited by 764

  24. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

    Authors: Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang, Mary Harlow Garfield, I Taylor, Marcia Dougan Moore, Ronald A. Peck, Howard A. Burris - Journal of Clinical Oncology 2020 cited by 165